Despite opposition from rare disease groups…

W&M Clears Bill That Limits Which Orphan Drugs Qualify For Tax Credits

By Beth Wang / September 16, 2021 at 10:30 AM

The House Ways & Means Committee on Wednesday (Sept. 15) passed as part of its reconciliation bill a provision that limits the number of rare disease drugs that can qualify for tax credits under the Orphan Drug Act, despite rare disease organizations’ assertions the provision would disincentivize research and could limit patients’ access to life-saving therapies.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.